(2R)-2-[(2S,3S,4R,5S,6R)-3-amino-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R)-2-[(2S,3S,4R,5S,6R)-3-amino-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoic acid
• 化学式: C₉H₁₇NO₇
• 分子量: 251.23
• InChiKey: MSFSPUZXLOGKHJ-BDIBXJNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  143
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• Method for synthesis of reactive conjugate clusters
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US10098959B2

  公开（公告）日：2018-10-16

  Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.

  本文提供了改进的方法，用于合成用于这些方法的反应性共轭簇和中间体。特别是，提供了通过减少所需的合成步骤来增强反应性共轭簇合成的改进。使用改进方法制备的反应性共轭簇不包括使用现有方法形成的任何酰基转移杂质。改进的方法还提供了整体产量的增加和比现有方法更具成本效益。
• COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3524680A1

  公开（公告）日：2019-08-14

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供的是具有共轭基团的低聚化合物。在某些实施方案中，低聚化合物与 N-乙酰半乳糖胺共轭。
• CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3546579A1

  公开（公告）日：2019-10-02

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供的是具有共轭基团的低聚化合物。在某些实施方案中，低聚化合物与 N-乙酰半乳糖胺共轭。
• COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3564374A1

  公开（公告）日：2019-11-06

  The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.

  本公开内容一般涉及用于研究、诊断和/或治疗的化学修饰寡核苷酸。在某些实施方案中，本公开内容描述了用于调节靶核酸的化合物和方法。在某些实施方案中，本公开内容描述了用于调节载脂蛋白 C-III 表达的化合物和方法。
• COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：EP3608406A1

  公开（公告）日：2020-02-12

  The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.

  本发明的实施方案提供了通过向受试者施用补体因子B（CFB）特异性抑制剂来治疗、预防或改善与补体替代途径失调相关的疾病的方法、化合物和组合物。